IPD Stock Overview
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.063|
|52 Week High||AU$0.20|
|52 Week Low||AU$0.049|
|1 Month Change||-1.56%|
|3 Month Change||5.00%|
|1 Year Change||-47.50%|
|3 Year Change||-64.00%|
|5 Year Change||-92.50%|
|Change since IPO||-92.59%|
Recent News & Updates
Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|IPD||AU Medical Equipment||AU Market|
Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned -20.8% over the past year.
Return vs Market: IPD underperformed the Australian Market which returned -10.8% over the past year.
|IPD Average Weekly Movement||15.1%|
|Medical Equipment Industry Average Movement||11.1%|
|Market Average Movement||9.4%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: IPD is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: IPD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics.
ImpediMed Fundamentals Summary
|IPD fundamental statistics|
Is IPD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IPD income statement (TTM)|
|Cost of Revenue||AU$1.41m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.011|
|Net Profit Margin||-188.09%|
How did IPD perform over the long term?See historical performance and comparison
Is IPD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IPD?
Other financial metrics that can be useful for relative valuation.
|What is IPD's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IPD's PS Ratio compare to its peers?
|IPD PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
EMV EMVision Medical Devices
Price-To-Sales vs Peers: IPD is expensive based on its Price-To-Sales Ratio (10.6x) compared to the peer average (10.3x).
Price to Earnings Ratio vs Industry
How does IPD's PE Ratio compare vs other companies in the AU Medical Equipment Industry?
Price-To-Sales vs Industry: IPD is expensive based on its Price-To-Sales Ratio (10.6x) compared to the Australian Medical Equipment industry average (7.3x)
Price to Sales Ratio vs Fair Ratio
What is IPD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||10.6x|
|Fair PS Ratio||38.5x|
Price-To-Sales vs Fair Ratio: IPD is good value based on its Price-To-Sales Ratio (10.6x) compared to the estimated Fair Price-To-Sales Ratio (38.5x).
Share Price vs Fair Value
What is the Fair Price of IPD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IPD (A$0.06) is trading below our estimate of fair value (A$0.81)
Significantly Below Fair Value: IPD is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: IPD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IPD is expected to become profitable in the next 3 years.
Revenue vs Market: IPD's revenue (53.1% per year) is forecast to grow faster than the Australian market (3.7% per year).
High Growth Revenue: IPD's revenue (53.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IPD's Return on Equity is forecast to be low in 3 years time (15.6%).
Discover growth companies
How has ImpediMed performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPD is currently unprofitable.
Growing Profit Margin: IPD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IPD is unprofitable, but has reduced losses over the past 5 years at a rate of 8.8% per year.
Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-25.3%).
Return on Equity
High ROE: IPD has a negative Return on Equity (-38.94%), as it is currently unprofitable.
Discover strong past performing companies
How is ImpediMed's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IPD's short term assets (A$46.7M) exceed its short term liabilities (A$7.2M).
Long Term Liabilities: IPD's short term assets (A$46.7M) exceed its long term liabilities (A$413.0K).
Debt to Equity History and Analysis
Debt Level: IPD is debt free.
Reducing Debt: IPD has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IPD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is ImpediMed current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|ImpediMed Dividend Yield vs Market|
|Market Bottom 25% (AU)||2.8%|
|Market Top 25% (AU)||7.2%|
|Industry Average (Medical Equipment)||1.9%|
|Analyst forecast in 3 Years (ImpediMed)||0%|
Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IPD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dave Anderson (68 yo)
Mr. David W. Anderson, B.S, also known as Dave, serves as Interim Chief Executive Officer of ImpediMed Limited since July 26, 2022. He was Chief Executive Officer of Highmark Western and Northeastern New Y...
Experienced Management: IPD's management team is considered experienced (3.9 years average tenure).
Experienced Board: IPD's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|09 Jun 22||SellAU$935,354||Orbis Investment Management Limited||Company||7,118,510||AU$0.13|
|30 Mar 22||BuyAU$2,473,438||Australian Ethical Investment Ltd.||Company||16,249,318||AU$0.17|
|18 Nov 21||SellAU$348,234||Orbis Investment Management Limited||Company||1,917,887||AU$0.18|
|02 Nov 21||BuyAU$5,435,855||Paradice Investment Management Pty Ltd.||Company||36,171,104||AU$0.15|
|29 Oct 21||SellAU$2,063,032||Paradice Investment Management Pty Ltd.||Company||12,000,000||AU$0.18|
|19 Oct 21||BuyAU$397,163||Orbis Investment Management Limited||Company||3,177,335||AU$0.12|
|19 Oct 21||SellAU$6,384,484||Orbis Investment Management Limited||Company||38,285,271||AU$0.17|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
ImpediMed Limited's employee growth, exchange listings and data sources
- Name: ImpediMed Limited
- Ticker: IPD
- Exchange: ASX
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: AU$112.139m
- Shares outstanding: 1.78b
- Website: https://www.impedimed.com
Number of Employees
- ImpediMed Limited
- 50 Parker Court
- Unit 1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IPD||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Oct 2007|
|IPDQ.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Oct 2007|
|IPD||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Oct 2007|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.